Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventing Malaria in School Children in Malawi
NCT06083688Phase 4Completed
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of dihydroartemisinin + piperaquine and sulfadoxine + pyrimethamine + amodiaquine in malaria (3 arms), sponsored by Liverpool School of Tropical Medicine. Primary endpoints: Number of participants with P. falciparum infection, Number of participants with anemia and 1 more. Started Oct 2024; status: completed.
02
Drugs
dihydroartemisinin + piperaquinesulfadoxine + pyrimethamine + amodiaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06083688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083688.